InnoCare Pharma Ltd. (INCPF)
1.55
0.00 (0.00%)
USD |
OTCM |
Sep 16, 16:00
InnoCare Pharma Enterprise Value : 1.833B for Sept. 16, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 16, 2026 | 1.833B |
| September 15, 2026 | 1.833B |
| September 14, 2026 | 1.833B |
| September 11, 2026 | 1.833B |
| September 10, 2026 | 1.833B |
| September 09, 2026 | 1.833B |
| September 08, 2026 | 1.833B |
| September 04, 2026 | 1.833B |
| September 03, 2026 | 1.833B |
| September 02, 2026 | 1.833B |
| September 01, 2026 | 1.833B |
| August 31, 2026 | 1.833B |
| August 28, 2026 | 1.833B |
| August 27, 2026 | 1.833B |
| August 26, 2026 | 1.833B |
| August 25, 2026 | 1.833B |
| August 24, 2026 | 1.833B |
| August 21, 2026 | 1.833B |
| August 20, 2026 | 1.833B |
| August 19, 2026 | 1.833B |
| August 18, 2026 | 1.833B |
| August 17, 2026 | 1.833B |
| August 14, 2026 | 1.833B |
| August 13, 2026 | 1.833B |
| August 12, 2026 | 1.833B |
| Date | Value |
|---|---|
| August 11, 2026 | 1.833B |
| August 10, 2026 | 1.833B |
| August 07, 2026 | 1.833B |
| August 06, 2026 | 1.833B |
| August 05, 2026 | 1.833B |
| August 04, 2026 | 1.833B |
| August 03, 2026 | 1.833B |
| July 31, 2026 | 1.833B |
| July 30, 2026 | 1.833B |
| July 29, 2026 | 1.833B |
| July 28, 2026 | 1.833B |
| July 27, 2026 | 1.833B |
| July 24, 2026 | 1.833B |
| July 23, 2026 | 1.833B |
| July 22, 2026 | 1.833B |
| July 21, 2026 | 1.833B |
| July 20, 2026 | 1.833B |
| July 17, 2026 | 1.833B |
| July 16, 2026 | 1.833B |
| July 15, 2026 | 1.833B |
| July 14, 2026 | 1.833B |
| July 13, 2026 | 1.833B |
| July 10, 2026 | 1.833B |
| July 09, 2026 | 1.833B |
| July 08, 2026 | 1.833B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ascletis Pharma, Inc. | 996.16M |
| CStone Pharmaceuticals Co. Ltd. | 1.116B |
| RemeGen Co., Ltd. | 5.418B |
| Adagene, Inc. | 300.12M |
| JW (Cayman) Therapeutics Co. Ltd. | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 20.16M |
| Revenue (Quarterly) | 89.38M |
| Total Expenses (Quarterly) | 68.74M |
| EPS Diluted (Quarterly) | 0.0117 |
| Gross Profit Margin (Quarterly) | 86.94% |
| Profit Margin (Quarterly) | 22.55% |
| Earnings Yield | 4.79% |
| Operating Earnings Yield | 3.77% |
| Normalized Earnings Yield | 4.736 |